Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Intact Vascular (Acquired by Philips) SDR Email:
Why this fails: The prospect is an expert interventional radiologist or vascular surgeon. They've seen this feature dump 1,000 times. There's zero indication you understand their specific facility's challenges, procedure volumes, or outcome metrics. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring interventional radiologists" (job postings - everyone sees this)
Start: "Your facility's Q3 2024 CMS radiation dose report shows 847 mGy average - 23% above the 690 mGy threshold" (government database with specific reporting period and record)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, facility identifiers.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - benchmarks already calculated, peer comparisons already identified, outcome gaps already quantified - whether they buy or not.
Company: Intact Vascular (Acquired by Philips)
Core Problem Solved: Interventional radiologists and vascular surgeons struggle to perform complex vascular interventions with precision, speed, and safety—requiring real-time imaging guidance, accurate vessel identification, and minimal radiation/contrast exposure during procedures.
Product Type: Medical Device / Imaging-Guided Intervention Platform (Tack Endovascular System® for minimal-metal dissection repair)
Target ICP: Hospital catheterization labs, vascular intervention centers, academic medical centers, and specialty interventional radiology departments. Focus on 200+ bed hospitals and major health systems performing high-volume peripheral interventions for chronic limb-threatening ischemia (CLTI) and peripheral artery disease (PAD).
Primary Buyer Personas: Interventional Radiologist, Vascular Surgeon, Director of Interventional Services, Chief Medical Officer (Hospital)
These messages are ordered by quality score (highest first). Each play demonstrates precise understanding of the prospect's situation using verifiable data sources.
Use CMS quarterly radiation dose reports to calculate facility-specific trajectory and predict when they'll trigger mandatory corrective action reporting. Show them the exact quarter-by-quarter projection with intervention points before penalties occur.
You're not just pointing out their current dose - you're predicting their future regulatory risk with specific timeline and consequences. The predictive analysis proves you studied THEIR data deeply, not a generic message. The urgency of "mandatory CMS corrective action" creates immediate need to respond.
Show each hospital their median fluoroscopy time and radiation dose for BTK repairs versus peer facility averages, cross-referenced with their CMS-reported radiation dose performance. Reveal specific technique optimization opportunities to reduce patient exposure while maintaining outcomes and meeting CMS quality targets.
Combines YOUR procedure efficiency data with THEIR public CMS performance. The 8-minute gap isn't just clinical - it's translated into revenue opportunity ($180K annual). Physicians care about both clinical excellence and practice economics. Asking "where your time extends vs peers" offers actionable improvement path.
This play requires aggregated procedure-level fluoroscopy time data from 30+ facilities performing BTK dissection repairs, segmented by vessel type and lesion complexity with median and percentile ranges.
Combined with facility-specific CMS public reporting. This synthesis is unique to your business.Provide each ASC or hospital IR department with their BTK dissection repair success rates and 12-month vessel patency compared to anonymized peer facilities of similar type and volume. Help them identify specific performance gaps and justify device adoption with peer-benchmarked outcome data.
Competitive intelligence physicians don't have access to. The 6-point patency gap is translated into actionable impact: 18 additional reinterventions annually. This isn't abstract - it's real patient care and practice economics. Offering "peer protocols" gives immediate value whether they buy or not.
This play requires aggregated clinical outcomes from 500+ BTK dissection repairs across 30+ facilities, including vessel patency at 12 months, reintervention rates, and success rates segmented by facility type and procedure volume tiers.
This is proprietary data only you have - competitors cannot replicate this play.Share specific case studies from peer vascular surgeons who dramatically reduced BTK stent deployment rates while improving reintervention outcomes. Provide their decision tree protocol showing exactly how they changed their approach to dissection repair.
The numbers are dramatic: 42% to 8% stent reduction with simultaneous reintervention improvement (28% to 14%). Surgeons trust peer surgeon experience more than vendor claims. Offering the "decision tree" provides immediate clinical value - they can implement it regardless of device choice.
This play requires detailed implementation case studies from physician customers showing procedural protocol changes, decision criteria, and longitudinal outcome improvements with specific metrics.
This is proprietary data only you have - competitors cannot replicate this play.Calculate facility-specific reintervention burden based on their reported BTK procedure volume and dissection rate. Show them exactly how many procedures they could avoid if they matched peer facility reintervention rates using structured protocols.
The "18 procedures" number is personalized to THEIR volume - not a generic statistic. This is both patient care impact (better outcomes) and practice economics (fewer unplanned procedures consuming capacity). The protocol comparison offers immediate value without requiring a purchase decision.
This play requires customer outcome data showing facility-specific reintervention rates and the ability to calculate facility-specific impact based on procedure volume from CMS data.
This is proprietary data only you have - competitors cannot replicate this play.Share implementation timeline and results from 4 comparable hospitals that achieved 35% fluoroscopy time reduction by adopting real-time vessel navigation guidance. Provide the case study showing their 18-month implementation and outcome trajectory.
Specific peer results (4 hospitals, 35% reduction, 18-month timeline) are far more credible than vendor claims. The 18-month implementation timeline is realistic - not promising overnight transformation. Hospitals trust peer hospital experience for major technology adoption decisions.
This play requires detailed implementation case studies from hospital customers showing baseline fluoroscopy times, intervention adopted, implementation timeline, and longitudinal efficiency outcomes.
This is proprietary data only you have - competitors cannot replicate this play.Identify hospitals reporting radiation doses 23%+ above CMS quality thresholds that are 3 quarters away from triggering potential Medicare reimbursement penalties. Mirror their exact reported dose from CMS data with specific facility ID and reporting period.
Uses THEIR actual reported CMS data (847 mGy) vs the threshold (690 mGy) with specific percentage over (23%). The penalty timeline is urgent and real - "3 quarters away" with exact start date (Q2 2025). The routing question ("Is someone tracking the dose reduction plan?") implies this is serious enough to need ownership.
Identify facilities showing year-over-year declines in 12-month BTK patency rates using CMS outcome data. Show them their specific performance decline with peer benchmark context and potential accreditation implications.
Year-over-year decline (77% to 71%) using THEIR CMS data is undeniable. The peer benchmark (79%) adds context. Mentioning "vascular surgery center accreditation" escalates the urgency - this isn't just clinical quality, it's regulatory/accreditation risk. The routing question identifies decision-maker.
This play requires the ability to track facility-specific outcome trends from CMS data and benchmark against peer standards derived from your aggregated customer outcome data.
Combined with public CMS reporting. This synthesis is unique to your business.Identify facilities with post-PTA dissection rates significantly higher than peer facilities (31% vs 19% peer average). Use CMS outcome data to show their gap and suggest either technique variation or equipment limitations affecting outcomes.
The 12-point dissection rate gap (31% vs 19%) is significant and uses peer comparison for context. Suggesting "technique variation or equipment limitations" gives them an out (not blaming the physician) while creating urgency to investigate. The routing question identifies who can address this.
This play requires the ability to calculate facility-specific dissection rates from CMS outcome data and benchmark against comparable centers using your aggregated customer data.
Combined with public CMS reporting. This synthesis is unique to your business.Identify facilities with significantly higher per-procedure costs for BTK dissection repairs compared to peer hospitals ($8,400 vs $5,200). Use CMS claims data to show the $3,200 gap likely reflects longer procedure times or additional device utilization beyond standard protocols.
Cost differential ($3,200 per procedure) is a significant financial concern for hospital leadership. The explanation ("longer procedure times or additional device utilization") gives clinical context without being accusatory. Hospitals under constant cost pressure will want to understand and address this variance.
This play requires the ability to analyze CMS claims data to calculate facility-specific procedure costs and benchmark against comparable centers using your customer data.
Combined with public CMS claims reporting. This synthesis is unique to your business.Identify hospitals using significantly higher contrast volume per peripheral intervention compared to peer facilities (215ml vs 160ml). Use CMS data to show the 55ml gap increases nephrotoxicity risk and suggests more repeat angiography runs than necessary.
The 55ml contrast volume differential is specific and verifiable from CMS data. Nephrotoxicity concern is legitimate patient safety issue that radiologists care deeply about. Suggesting "more repeat angiography runs" provides clinical explanation without being accusatory. The routing question is appropriate for radiology leadership.
Old way: Spray generic device feature messages at interventional radiologists. Hope someone replies.
New way: Use CMS quality data and your aggregated outcome benchmarks to find facilities with specific performance gaps. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your Q3 2024 CMS radiation dose report shows 847 mGy - 23% above the 690 mGy threshold" instead of "I see you're performing vascular interventions," you're not another medical device sales rep. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources (CMS quality reporting, facility outcome benchmarks) with specific painful situations (above-threshold radiation doses, declining patency rates, procedure inefficiency). Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable public data or proprietary aggregated customer outcomes. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| CMS Hospital Outpatient Quality Reporting Program (OQR) | facility_name, facility_id, radiation_dose_reporting, quality_measures_outcomes, patient_safety_indicators | Radiation dose thresholds, quarterly performance tracking, procedure quality metrics |
| CMS Hospital Compare (Medicare.gov) | hospital_name, quality_measures (100+), mortality_rates, complication_rates, safety_culture_scores | Facility-level quality benchmarking, outcome trends, peer comparisons |
| CMS Ambulatory Surgical Center Quality Reporting (ASCQR) | facility_name, ccn_certification_number, quality_measures, complication_rates, procedure volumes | ASC performance metrics, vascular specialty centers, procedure volume analysis |
| Company Internal Data (Aggregated Customer Outcomes) | vessel_patency_rates, reintervention_rates, fluoroscopy_time, radiation_dose, facility_type, procedure_volume | Peer benchmarks, outcome comparisons, efficiency metrics, protocol case studies |
| CMS Hospital Claims Data | facility_id, procedure_codes, costs_per_procedure, volume_by_procedure_type | Cost variance analysis, procedure volume calculations, financial impact modeling |
| ACR Accredited Facility Search | facility_name, location, accreditation_status, imaging_modalities, accreditation_date | Identifying ACR-accredited IR facilities, tracking accreditation compliance |
| ACS-Verified Trauma Center Directory | hospital_name, facility_location, trauma_center_level, vascular_care_program | Identifying Level I/II trauma centers with vascular capability |
| Joint Commission Accredited Organizations Database | organization_name, location, accreditation_status, specialty_services | Identifying accredited hospitals with vascular programs |